Supernus announces FDA approval of Orenitram Supernus Pharmaceuticals (SUPN) announced that the FDA approved Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity. Supernus developed the extended release formulation of Orenitram under a Development and License Agreement with United Therapeutics (UTHR). The product uses EnSoTrol, Supernus' novel osmotic technology platform. Per the license agreement between Supernus and United Therapeutics, United Therapeutics will pay Supernus certain milestone fees and royalties associated with the commercialization of the product worldwide.
News For SUPN;UTHR From The Last 14 Days
Check below for free stories on SUPN;UTHR the last two weeks.